Sitagliptin Phosphate Monohydrate CAS 654671-77-9 Purity >99.0% (HPLC) API Factory High Quality

Short Description:

Chemical Name: Sitagliptin Phosphate Monohydrate

CAS: 654671-77-9

Purity: >99.0% (HPLC on the dried basis)

Appearance: White to Off-White Crystalline Powder

For the treatment of type II diabetes mellitus

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name Sitagliptin Phosphate Monohydrate
Synonyms (R)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one phosphate monohydrate
CAS Number 654671-77-9
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C16H20F6N5O6P
Molecular Weight 523.3240802
Melting Point 202.0~204.0℃
Water Solubility Soluble in Water
Specific Rotation -18.0°~-23.0° (C=1, Water)
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White to Off-White Crystalline Powder
Identification by HPLC The retention time of sample is concordant with reference standard
IR-Infrared Spectrum The IR Absorption Spectrum of the sample shall be concordant with that of standard spectrum
Phosphate Complies
Purity / Analysis Method >99.0% (HPLC on the dried basis) 
Water Content (K.F) 3.3%~4.4%
Residue on Ignition ≤0.20%
Sulphate ≤0.02%
Chloride ≤0.05%
Chiral Impurity <0.50%
Related Substances
Single Impurity <0.50%
Total Impurities <1.0%
Ethyl Acetate <0.50%
Heavy Metals <20ppm
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement.

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.

Advantages:

1

FAQ:

Application:

Sitagliptin Phosphate Monohydrate (CAS: 654671-77-9), a new drug for the treatment of type 2 diabetes. In August 2009, the drug was approved by the European Union as a first-line drug for the treatment of type 2 diabetes. Sitagliptin Phosphate is the first FDA-approved dipeptidyl peptidase-IV inhibitor to be used in the treatment of type 2 diabetes by far, under the trade name Januvia. Dipeptidylpeptidase Ⅳ (DPP-Ⅳ) rapidly and effectively degrades GLP-1, GLP-1, which is the most effective stimulator of insulin production and secretion Therefore, inhibition of DPP-IV can enhance the role of endogenous GLP-1, thereby increasing blood insulin levels, thereby reducing and maintaining blood glucose levels in diabetic patients. At present, medicine has confirmed that DPP-IV inhibitor is a new type of anti-diabetic drug, and clinical results show that the drugs have a good hypoglycemic effect. Because GLP-1 plays a glucose-dependent role in promoting insulin production and secretion, common adverse reactions such as hypoglycemia and weight gain caused by the use of antidiabetic drugs do not occur.

  • Write your message here and send it to us